Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus

Journal of Investigative Medicine

Volumn 61, Issue 8, 2013, Pages 1161-1164

  Topuz, Mustafa ^a   Celik, Ahmet ^b   Aslantas, Tutku ^a   Demir, Ayse Kevser ^a   Aydin, Suna ^c   Aydin, Suleyman ^d  

^a Cardiology   (Turkey)

^b MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Elazig Education and Research Hospital ^*  (Turkey)

^d FIRAT UNIVERSITY   (Turkey)

Author keywords

Adropin; Endothelial dysfunction; Endothelium; Flow mediated dilatation; Type 2 diabetes mellitus

Indexed keywords

ADROPIN; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PROTEIN; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW MEDIATED DILATATION; HUMAN; INSULIN TREATMENT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; VASODILATATION; VENOUS BLOOD; BLOOD SAMPLING; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; DOPPLER ULTRASONOGRAPHY; GLUCOSE BLOOD LEVEL; PREDICTION;

BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; VASODILATION;

EID: 84896693281     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000003     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26:77-82.
3. Stehouwer CD, Lambert J, Donker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
4. Zhang H, Dellsperger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol. 2012;107:237.
5. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 2009;335:165-189.
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
7. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387-423.
8. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122:S185-S192.
9. Celik A, Balin M, Kobat MA, et al. Deficiency of a new protein associated with cardiac syndrome x; called adropin. Cardiovasc Ther. 2013;31:174-178.
10. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013;41: 375-380.
11. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540-1545.
12. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-876.
13. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
14. De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis. 1997;39:325-342.
15. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995;38:105-128.
16. Bassenge E. Clinical relevance of endothelium-derived relaxing factor (EDRF). Br J Clin Pharmacol. 1992;34(suppl 1):37S-42S.
17. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol. 1995;15:1114-1120.
18. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I. Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
19. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II. Animal and human studies. Circulation. 2003;108:2034-2040.
20. Nitenberg A, Valensi P, Sachs R, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993;42:1017-1025.
21. Zenere BM, Arcaro G, Saggiani F, et al. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care. 1995;18:975-982.
22. Cacoub P, Carayon A, Dorent R, et al. Endothelin: the vasoconstrictor of the 1990's? Rev Med Interne. 1993;14:229-232.
23. Blann A. Von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci. 1993;50:125-134.
24. Takahashi H, Ito S, Hanano M, et al. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol. 1992;41:32-39.
25. Richardson M, Hadcock SJ, DeReske M, et al. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb. 1994;14:760-769.
26. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
27. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997;129:111-118.
28. Chan SY, Mancini GBJ, Kuramoto L, et al. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1037-1043.
29. Nair BM, Viswanathan V, Snehalatha C, et al. Flow mediated dilatation and carotid intimal media thickness in South Indian type 2 diabetic subjects. Diabetes Res Clin Pract. 2004;65:13-19.
30. Henry RM, Ferreira I, Kostense PJ, et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis. 2004;174:49-56.
31. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97:3783-3791.
32. Lian W, Gu X, Qin Y, et al. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011;50:1523-1527.